Filip Janku - Jan 2, 2024 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Chief Medical Officer
Signature
/s/ Markus Warmuth, Attorney-in-Fact
Stock symbol
GLUE
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 04:15 PM
Previous filing
Jan 4, 2023
Next filing
Sep 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GLUE Common Stock 5.25K Jan 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +121K $0.00 121K Jan 2, 2024 Common Stock 121K $5.71 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 5,252 shares previously acquired under the Issuer's 2021 Employee Stock Purchase Program.
F2 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.